DeepMed Research

Mabwell (Shanghai) Bioscience Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2017-05-12

Employees: 1.4K

Market Cap: -

Website: https://www.mabwell.com

Clinical Trials

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: 9MW2821

First Posted Date: 2023-03-17

Last Posted Date: 2023-03-17

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05773937

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Beijing University Cancer Hospital, Beijing, Beijing, China

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Phase 1

Recruiting

Conditions: Tumor
Pulmonary Fibrosis

Interventions: Drug: 9MW3811 injection
Drug: Placebo

First Posted Date: 2023-02-23

Last Posted Date: 2023-06-13

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT05740475

Locations: 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia

6MW3511 in Patients With Advanced Solid Tumor

Phase 1

Not yet recruiting

Conditions: Solid Tumors

Interventions: Drug: Intravenous Infusion

First Posted Date: 2022-09-01

Last Posted Date: 2022-09-01

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 272

Registration Number: NCT05524194

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Phase 2

Not yet recruiting

Conditions: Lymphoma

Interventions: Drug: 6MW3211

First Posted Date: 2022-07-07

Last Posted Date: 2022-07-07

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05446688

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Phase 1

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: 6MW3211 injection with Intravenous Infusion

First Posted Date: 2022-07-07

Last Posted Date: 2023-03-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05448599

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Clear Cell Renal Cell Carcinoma

Interventions: Drug: 6MW3211

First Posted Date: 2022-06-30

Last Posted Date: 2022-08-17

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05440045

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Phase 2

Conditions: Advanced Lung Cancer

Interventions: Drug: 6MW3211

First Posted Date: 2022-06-24

Last Posted Date: 2022-06-24

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05431569

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Suspended

Conditions: Solid Tumors

Interventions: Drug: 8MW2311

First Posted Date: 2022-06-13

Last Posted Date: 2024-11-20

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 216

Registration Number: NCT05416749

Locations: 🇨🇳
The first affiliated hospital of bengbu medicial college, Bengbu, Anhui, China
🇨🇳
Hunan cancer hospital, Changsha, Hunan, China
🇨🇳
Jian Zhang, Shanghai, Shanghai, China

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Phase 2

Conditions: Skin Infection

Interventions: Combination Product: 9MW1411 injection 2 combined with Linezolid
Combination Product: 9MW1411 injection placebo combined with Linezolid
Combination Product: 9MW1411 injection 1 combined with Linezolid

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT05339802

Locations: 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Phase 3

Conditions: Diabetic Macular Edema

Interventions: Drug: 9MW0813
Drug: Aflibercept

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-12

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 346

Registration Number: NCT05324774

Locations: 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy